GSK Can Seize Chance In Anemia After Rivals Rejected But FDA Caution Will Remain
Daprodustat Filing Accepted In US
GSK’s drug is the first in the class to show non-inferiority to standard therapy in safety, but the data still contains areas of doubt.
You may also be interested in...
Keeping Track: TGT’s Ukoniq Is Latest PI3K Inhibitor To Fall; GSK’s Daprodustat, Aeglea’s Pegzilarginase Headline Submissions
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
As three big players get set to reveal pivotal data for adult RSV vaccines, Bavarian Nordic seals a deal for its candidate that could still claim a sizeable niche if a late-stage trial delivers.
Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.